SREBF1 and glioblastoma: Importantly, by targeting key enzymes of FA synthesis pathways, such as SREBP-1, acetyl-CoA carboxylase ACC, and FA synthase (FASN), or by blocking the fatty acid elongase 2 (ELOVL2), which catalyzes the elongation of fatty acids, glioblastoma cell growth, and the inhibition of tumor initiation or promotion of apoptosis [50,51,52].